Journal
CURRENT DIABETES REPORTS
Volume 8, Issue 3, Pages 233-238Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-008-0040-z
Keywords
-
Categories
Ask authors/readers for more resources
Selective insulin resistance influences pathogenesis and treatment of type 2 diabetes and metabolic syndrome. Downregulation of the antiatherogenic pathway and maintained activity of the proatherogenic and cancerogenic pathways lead to atherosclerosis and cancer. Exogenous insulin added to compensatory hyperinsulinemia might worsen the primary end points, resulting in potential increase in cardiovascular and cancer events in spite of improvement of surrogate metabolic end points. Conversely, metformin can improve primary and surrogate end points.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available